Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.
Özdemir BC, Espinosa da Silva C, Arangalage D, Monney P, Guler SA, Huynh-Do U, Stirnimann G, Possamai L, Trepp R, Hoepner R, Salmen A, Gerard CL, Hruz P, Christ L, Rothschild SI. Özdemir BC, et al. Among authors: hruz p. Cancer Immunol Immunother. 2023 Jul;72(7):1991-2001. doi: 10.1007/s00262-023-03436-0. Epub 2023 Apr 5. Cancer Immunol Immunother. 2023. PMID: 37017694 Free PMC article. Review.
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients.
Özdemir BC, Espinosa da Silva C, Arangalage D, Monney P, Guler SA, Huynh-Do U, Stirnimann G, Possamai L, Trepp R, Hoepner R, Salmen A, Gerard CL, Hruz P, Christ L, Rothschild SI. Özdemir BC, et al. Among authors: hruz p. Cancer Immunol Immunother. 2023 Jul;72(7):2003-2004. doi: 10.1007/s00262-023-03456-w. Cancer Immunol Immunother. 2023. PMID: 37154850 Free PMC article. No abstract available.
AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells.
Pop OT, Geng A, Flint E, Singanayagam A, Ercan C, Possamai L, Patel VC, Kuenzler P, Meier MA, Soysal S, Hruz P, Kollmar O, Tatham KC, Ward JK, Müllhaupt B, Weber A, Wendon J, Niess JH, Heim M, Semela D, Weston C, Antoniades CG, Terracciano LM, Triantafyllou E, Brenig RG, Bernsmeier C. Pop OT, et al. Among authors: hruz p. Cell Mol Gastroenterol Hepatol. 2023;16(1):17-37. doi: 10.1016/j.jcmgh.2023.03.007. Epub 2023 Mar 31. Cell Mol Gastroenterol Hepatol. 2023. PMID: 37004869 Free PMC article.
Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study.
Biedermann L, Schlag C, Straumann A, Lucendo AJ, Miehlke S, Vieth M, Santander C, Ciriza de Los Rios C, Schmöcker C, Madisch A, Hruz P, Hayat J, von Arnim U, Bredenoord AJ, Schubert S, Halstead M, Pfurr S, Mueller R, Schoepfer AM, Attwood S; International EOS-2 Study Group. Biedermann L, et al. Among authors: hruz p. Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01088-7. doi: 10.1016/j.cgh.2024.10.034. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39694205 Free article.
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial.
Biedermann L, Doulberis M, Schreiner P, Nielsen OH, The FO, Brand S, Burk S, Hruz P, Juillerat P, Krieger-Grübel C, Leu K, Leventhal GE, Misselwitz B, Scharl S, Schoepfer A, Seibold F, Herfarth H, Rogler G. Biedermann L, et al. Among authors: hruz p. Nutrients. 2024 Dec 4;16(23):4197. doi: 10.3390/nu16234197. Nutrients. 2024. PMID: 39683589 Free PMC article. Clinical Trial.
Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey.
Wespi N, Vavricka S, Brand S, Aepli P, Burri E, Misselwitz B, Seibold F, Hruz P, Peyrin-Biroulet L, Schoepfer A, Biedermann L, Sokollik C, Rogler G, Greuter T. Wespi N, et al. Among authors: hruz p. United European Gastroenterol J. 2024 Sep 8. doi: 10.1002/ueg2.12657. Online ahead of print. United European Gastroenterol J. 2024. PMID: 39246002 Free article.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
167 results